Biohaven (BHVN) shares were lower premarket Monday after the biopharmaceutical company said a study of its experimental drug for spinal muscular atrophy did not achieve a "statistically significant difference" compared with placebo and standard of care at 48 weeks.
The company said the experimental treatment "showed clinically meaningful improvements" in motor function for patients in the study.
Biohaven said it intends to accelerate taldefgrobep alpha clinical plans in Q4 and engage with the US Food and Drug Administration on a path forward for the treatment.
Spinal muscular atrophy is a disorder characterized by the loss of motor neurons, atrophy of limb muscles, and muscle weakness that is often fatal.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。